Scarica l'app Stockscreener
3.70
1.09%
0.04
Dopo l'orario di chiusura:
3.57
-0.13
-3.51%
Precedente Chiudi:
$3.66
Aprire:
$3.44
Volume 24 ore:
9,716
Relative Volume:
0.42
Capitalizzazione di mercato:
$9.86M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+18.02%
1M Prestazione:
+44.51%
6M Prestazione:
-3.12%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.3145
$3.80
Intervallo di 1 settimana:
$3.12
$3.80
Portata 52W:
$1.96
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
Nome
Cosciens Biopharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta CSCI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSCI
Cosciens Biopharma Inc
|
3.70 | 9.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cosciens Biopharma Inc Borsa (CSCI) Ultime notizie
COSCIENS Biopharma Sets Date for Annual Meeting Amid Strategic Shifts - TipRanks
Fennec Pharmaceuticals: Top 10 Undervalued Biotechnology Industry Stocks (FRX) - The Globe and Mail
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
COSCIENS Biopharma appoints Anna Biehn as new CEO amid leadership change - N24.com.tr
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Bi - GuruFocus
COSCIENS Biopharma (CSCI) Names Anna Biehn as New CEO | CSCI Sto - GuruFocus
COSCIENS Biopharma names new CEO Anna Biehn By Investing.com - Investing.com Canada
COSCIENS Biopharma names new CEO Anna Biehn - Investing.com Australia
COSCIENS Biopharma names Anna Biehn as new CEO By Investing.com - Investing.com South Africa
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$1.89 loss in FY 2023) - simplywall.st
COSCIENS Biopharma names Anna Biehn as new CEO - Investing.com Australia
Cosciens Biopharma appoints Biehn as CEO - TipRanks
COSCIENS Biopharma Appoints Anna Biehn as New CEO to Drive Growth in Natural-Based Products - TipRanks
Cosciens Biopharma Appoints Anna Biehn as Chief Executive Officer - marketscreener.com
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer - The Manila Times
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023) - Yahoo Finance
COSCIENS Biopharma Reports Revenue Growth and Strategic Repositioning - MSN
Cosciens Biopharma Charts New Path Following Ceapro Merger - Finimize
COSCIENS Biopharma reports Q4 and full year 2024 results - Investing.com Australia
COSCIENS Biopharma: Q4 Earnings Snapshot - CT Insider
COSCIENS Biopharma reports Q4 and full year 2024 results By Investing.com - Investing.com South Africa
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 202 - GuruFocus
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
Natural Products Drive COSCIENS Growth: Revenue Jumps 35% as Pipeline Advances - Stock Titan
COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays - TipRanks
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Lelezard
COSCIENS Biopharma Faces Trading Halt: What Investors Need to Know - AInvest
Regulatory Alert: COSCIENS Faces Management Trading Ban Over Missing Financial Reports - Stock Titan
Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? - Insider Monkey
COSCIENS Biopharma flags potential reporting delay By Investing.com - Investing.com Australia
Thursday’s 10 Worst-Performing Stocks - Insider Monkey
Sector Update: Health Care Stocks Edge Higher Late Afternoon -March 20, 2025 at 04:02 pm EDT - MarketScreener
Top Midday Decliners -March 20, 2025 at 02:10 pm EDT - MarketScreener
COSCIENS Biopharma flags potential reporting delay - Investing.com
COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger Complexities - TipRanks
Cosciens Biopharma Inc Azioni (CSCI) Dati Finanziari
Non sono disponibili dati finanziari per Cosciens Biopharma Inc (CSCI). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):